Patient empowerment and education by IT-supported pathways reduce postoperative pain intensity and rate of pain chronification after thoracic surgery
Not Applicable
- Conditions
- R52.2Other chronic pain
- Registration Number
- DRKS00019087
- Lead Sponsor
- niversitätsmedizin Essen Ruhrlandklink Zentrum für Anästhesiologie und Schmerztherapie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 946
Inclusion Criteria
Business-ready patients who are German and
speak and understand the German language.
Thoracotomy or VATS OP duration >30 min.
Smartphone owner or internet access
Exclusion Criteria
Patients with contraindications to opioids or non-opioids
estimated life expectancy of 1 year
Addiction (except Nicotinabusus)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reducing the incidence of chronical postthoracic pain syndrome and neuropathic pain is the primary objective. We will analyse the pain rate of the intervention group compared with the pain rate of the control group after 6 months. The pain rate is defined as a pain score over 0 (numeric rating scale 0-10).It is assumed that all patients with a pain score over 0 suffer from chronical postthoracic pain syndrome. Furthermore we analyse the rate of patients with neuropathic pain, which is detectable with the PainDETECT questionnaire. We collect the data of the PainDETECT preoperative and after 1, 3 and 6 months. It is assumed that all patients with a score over 18 suffer from neuropathic pain.
- Secondary Outcome Measures
Name Time Method Improvement of the quality of life, reducing the costs and cost effectiveness is the secondary objective. We will analyse the quality of life of the intervention group compared to the control group preoperative and after 1, 3 and 6 months with the questionnaires SF-12 and EQ-5D-5L. Furthermore we analyse the costs as well as the cost effectiveness (cost-effectiveness analysis and cost-benefit analysis) of the IT-supported clinical pathways as well as the patient empowerment/education compared to the standard pain therapy of the control group, which are insured at the AOK. The data include the expenses in the areas of inpatient care, out-patient medical care, pharmaceutical supply, supply of aids and rehabilitation. As clinical effect parameters we will use cases of non chronification (cost-effectiveness analysis) and the quality of life (cost-benefit analysis).